Home  Top Stories  Sports  Entertainment  Health News  Business  Personal Finance 
Real Estate  Business Finance  Insurance  Consulting 
Tax News  Forum




Featured Articles






Plavix and Aspirin Together is not Better than Aspirin Alone in Preventing a First Heart Attack in High Risk Patients with Heart Disease

March 13th 2006

Plavix and Aspirin Together is not Better than Aspirin Alone in Preventing a First Heart Attack in High Risk Patients with Heart Disease


A new study shows that patients adding Plavix to aspirin does not prevent first heart attacks in people at high risk.  Previous research has shown the anti-clotting drug Plavix and aspirin to be helpful in reducing the risk of subsequent heart attacks. It is because of these earlier findings that many physicians assumed it would help prevent the initial heart attack.

The researchers studied 15,603 high risk patients who either had been diagnosed with heart disease or had multiple-risk factors, such as diabetes, hardening of the arteries, high blood pressure or high cholesterol.  The subjects were from 32 different countries, and were all over the age of 45.  The results were presented at the American College of Cardiology conference Sunday by Dr. Eric Topol and Dr. Deepak Bhatt of the Cleveland Clinic.


Aspirin may help prevent a second heart attack in people that have already had one.  The researchers believe that if you have never had a heart attack, aspirin may not be that useful in preventing one, according to Christian Nordqvis in Medical News Today.

There was a warning from the Sunday session. Dr. Marc Pfeffer of the Harvard Medical School and Dr. John Jarcho of the Brigham and Women's Hospital in Boston said in an accompanied editorial that "The absence of a clear benefit, in terms of clinical outcome, coupled with the increased rate of bleeding ... argues against the use of dual (anti-clotting) therapy in this patient population," 

The combination therapy may also harm patients who smoke or have diabetes, according to Nordqvis.  Thomas H. Maugh II wrote in the LA Times that the researchers found that the drug appeared to have a modest benefit in a subgroup of patients who had heart disease but had not had a heart attack.


The findings are considered a significant setback for the drug's manufacturers, Sanofi-Aventis and Bristol-Myers Squibb Co.  Plavix (clopidogrel) is the number 2 drug in the world in terms of sales, generating $6.2 billion in revenue.  The drug costs about $4 per pill.

The research will appear in the April 20 issue of the New England Journal of Medicine.  In the Journal the researchers conclude that “there was a suggestion of benefit with clopidogrel treatment in patients with symptomatic atherothrombosis and a suggestion of harm in patients with multiple risk factors. Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes.”

Comment on this Article at our Forum

Submit your own Article

Lung and Heart News

  RSS Feed to our Heart/Lung News

  RSS Feed to health News

  RSS Feed to all of our News

Add to Google Add to My AOL
Add to My Yahoo! Subscribe with Pluck RSS reader
Subscribe in NewsGator Online
Add this feed to Your C-Net
Subscribe in Bloglines Subscribe in Rojo

By Dan Wilson
Best Syndication

Books on Heart Disease

Keywords and misspellings:  coranary micro-vascular disfunction iscemic iskemic ishcemic ishcemia angiograf blood presure stroke embolism imbolism embilism embelism bloode clot


About   Contact   site map

Copyright 2005 Best Syndication                                            Last Updated Saturday, July 10, 2010 09:50 PM